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Abstract: The threatening notoriety of pancreatic cancer mainly arises from its negligible early
diagnosis, highly aggressive progression, failure of conventional therapeutic options and consequent
very poor prognosis. The most important driver genes of pancreatic cancer are the oncogene KRAS
and the tumor suppressors TP53, CDKN2A, and SMAD4. Although the presence of few drivers,
several signaling pathways are involved in the oncogenesis of this cancer type, some of them with
promising targets for precision oncology. Pancreatic cancer is recognized as one of immunosuppressive
phenotype cancer: it is characterized by a fibrotic-desmoplastic stroma, in which there is an intensive
cross-talk between several cellular (e.g., fibroblasts, myeloid cells, lymphocytes, endothelial, and
myeloid cells) and acellular (collagen, fibronectin, and soluble factors) components. In this review;
we aim to describe the current knowledge of the genetic/biological landscape of pancreatic cancer
and the composition of its tumor microenvironment; in order to better direct in the intrinsic labyrinth
of this complex tumor type. Indeed; disentangling the genetic and molecular characteristics of cancer
cells and the environment in which they evolve may represent the crucial step towards more effective
therapeutic strategies
Keywords: pancreatic cancer; oncogene; tumor suppressor; signaling pathway; tumor
microenvironment; targeted therapy
1. Introduction
Pancreatic cancer (PC) is perhaps the most lethal among solid tumors worldwide; although
incidence varies between different countries, PC is the seventh leading cause of global cancer-related
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deaths in industrialized countries, the fourth in Italy, and the third in the United States of America [1–3].
Long-term survival is poor, with a five-year survival rate ranging from 5% to 8% [3]. The threatening
notoriety of PC primarily arises from the lack of sensitive and specific biomarker(s) for detection and its
negligible early diagnosis: indeed, the vast majority of PC patients are not eligible for surgical resection
at the time of the diagnosis and present with a locally advanced or metastatic stage [4]. Moreover,
even in patients undergoing potentially curative surgical resection the disease usually recurs within
2–3 years in the majority of cases.
As highlighted above, such PC unique aggressiveness is due to both specific genetic and molecular
traits (acquired through either a stepwise or a chromothripsis-mediated simultaneous loss of multiple
tumor suppressors and gain of multiple oncogenes), but to complex interactions with a generally
obstructive and immunosuppressive tumor microenvironment (TME), which confer a highly malignant
phenotype, as well (Figure 1) [5,6].
Figure 1. According to PanIN and IPMN stage, a time-manner dependent accumulation of point
mutations in oncogenes and tumor suppressor genes, epigenetic alterations and chromosomal structural
variants are represented. Furthermore, PC is mainly represented by desmoplastic stroma and
immunosuppressive TME: indeed, cell populations, collagen organization, and cytokines are profoundly
different between normal pancreatic tissue and advanced PC. DC, dendritic cells; GNAS, guanine
nucleotide binding protein, alpha stimulating; IPMN, intraductal papillary mucinous neoplasm; KRAS,
Kirsten rat sarcoma; MDSC, myeloid-derived suppressor cells; PanIN, pancreatic intraepithelial lesion;
PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; PSC, pancreatic stellate cells; TME,
tumor microenvironment; TP53, tumor suppressor protein 53.
Although combination chemotherapy has to some extent improved cure rates, survival, and
quality of life in both early and advanced PC, anti-angiogenic drugs, molecularly targeted agents and
immune checkpoint inhibitors have proven ineffective, so far, in PC [7,8]. Even the combination of
therapies simultaneously targeting multiple crosstalking pathways has failed to confer clinical benefit
in the absence of predictive biomarkers able to identify patients who will most likely respond to specific
therapeutic combinations. This is well exemplified by the recent failure of a theoretically rational
combination of MEK and AKT inhibitors [9]. In that respect, our group has recently identified PTEN-loss
status as a predictive biomarker of synergistic pharmacologic interactions between mitogen-activated
protein kinase (MAPK)- and phosphoinositide-3-kinase (PI3K)-inhibitors, in several preclinical models
in vitro; when applied to PC the combination of data obtained in vitro and the relative rarity of
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complete loss of PTEN function in pancreatic ductal adenocarcinoma (PDAC) could have predicted
the clinical failure of the MEK/AKT combination in unselected PC patients [9,10].
In recent years the genetic pathway to PC development (encompassing a relatively restricted set
of recurrently altered genes, such as KRAS (Kirsten rat sarcoma), TP53 (tumor suppressor protein
53), CDKN2A (cyclin dependent kinase inhibitor 2A), and SMAD4 (SMAD family member 4), and
molecular pathways) has been elucidated to an unprecedented extent; on the other hand, it is now
clear that an intense crosstalk between stroma and cancer cells, mediated by soluble factors, leads to
extensive fibrosis and deposition of extracellular matrix (ECM) proteins, resulting in poor perfusion
and hypoxic conditions which, in turn, favor the evolution of aggressive clones (Figure 1). The
molecular mechanisms of such interactions are only beginning to be elucidated and the Ariadne’s
string linking specific tumor genetic/molecular background(s), to the production of specific sets of
soluble factors and to the formation of an obstructive and immune suppressive TME will need to be
precisely identified to develop new and effective therapeutic strategies to defeat such an aggressive
and therapy resistant disease.
2. Driver Genes Alterations and Molecular Pathways to PC Development
2.1. Precursor Lesions
The high-aggressive PC represents a late event in a time-manner dependent sequence of genetic
and molecular events, such as pancreatic intraductal neoplasia (PanIN) and intraductal papillary
mucinous neoplasm (IPMN). PanIN is the most common PC precursor. It is a microscopic (<0.5 cm)
intraductal lesion that can be found >80% of pancreas with invasive carcinoma [11,12]. PanIN is
composed by cuboid to columnar mucinous cells; the new World Health Organization classification
distinguishes low- from high-grade dysplasia to classify possible varying degrees of dysplasia [12].
Seminal papers on this topic showed molecular evidences of the progression from PanIN to PC, with
early lesions (low-grade PanINs) displaying KRAS somatic mutations [13–15]. In PanIN carcinogenetic
cascade, the TP53 and SMAD4 inactivations appear as very late events, often exclusive of an already
existing invasion [16]. Another important PC precursor in certainly represented by IPMN. IPMN
is a grossly-visible lesion (>1 cm by definition), with intraductal growth and papillary architecture,
composed of mucinous cells. IPMN dysplasia also should be classified in low- and high-grade [12].
Based on the involvement in pancreatic ductal tree, IPMN could be categorized in: (1) main-duct IPMN
(involvement of only Wirsung’s duct), (2) branch-duct IPMN (involvement of only secondary ducts),
(3) mixed IPMN (contemporary involvement of the main and the branch ducts). This classification
displays very important implications in clinical practice, indeed the main-duct IPMN shows higher
risks towards evolution in PC, as compared to the others two [12,17]. From a histological point of view,
IPMN can be classified into four subgroups: gastric, pancreatobiliary, intestinal, and oncocytic [12].
Even this classification shows a clinical impact, due to the association of the pancreatobiliary subtype
with PC development [18,19]. From a molecular point of view, the most frequently mutated genes
in IPMN are GNAS (guanine nucleotide binding protein, alpha stimulating) and KRAS, which are
altered in up to 60% and to 80% of cases, respectively [12,20,21]. Notably, recent researches highlighted
that the IPMN oncogenetic process is regulated by two different pathways: the first, linked to GNAS
mutations, involves intestinal IPMN progressing to colloid adenocarcinomas (a PC variant reach in
extracellular mucin), and the second, driven by KRAS mutations, is typical of pancreatobiliary IPMN
and leads to conventional PC [20,21].
2.2. Driver Genes Alterations
Our knowledge of the molecular bases of PC has recently greatly improved, owing to advances in
technology (next-generation sequencing—NGS) and consortia-based approaches, the latter enabling
the collection of large cohorts of carefully annotated specimens. From a genetic point of view, PC
appears as a complex disease, with a number of genes being altered through different mechanisms
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including point mutations, chromosomal aberrations, and epigenetic mechanisms, resulting in an
“intermediate” tumor mutational burden [22]. Four genes, also called “PC genetic mountains”, are most
commonly mutated: the KRAS oncogene, the TP53, the CDKN2A, and the SMAD4 tumor suppressor
gene (Figure 1). Other genes altered at a lower but not-negligible prevalence are also called “PC
genetic hills” [23,24]. Notably, alterations affecting the most important genetic drivers of PC can be
demonstrated on tissue samples as well as by liquid biopsy, with reliable sensitivity and specificity [25].
2.2.1. KRAS
The KRAS is an oncogene located on chromosome 12, and is the most frequently mutated gene in
PC (>90% of cases); the vast majority of activating mutations occurs at codons 12, 13, or 61 [23–27].
This oncogene encodes a small GTPase, that is switched on and off by cycling between the GTP-bound
(active) and GDP-bound (inactive) forms. It acts as a transducer-moderator, interacting with cell
surface receptors (receptor tyrosine kinases); once triggered, it stimulates several intracellular effector
pathways, which drive very important modifications of cancer cells, such as increased proliferation,
metabolism and migration, immune system evasion, and apoptosis blockade [28]. These downstream
pathways include, among others, MAPK and PI3K. Notably, attempts at inhibiting the activity of
the mutant KRAS oncoprotein have been unsuccessful, thus rendering such target undruggable so
far and, perhaps, one of the most important reasons for PC’s high-mortality rate [29]. Very recently,
new data on KRAS G12C-selective inhibitors and other new-generation KRAS-targeted approaches
have been reported, raising renewed hope that we could one day target the main genetic PC driver
directly or through repurposed drugs [30]. Mutations affecting KRAS represent an early event in PC
carcinogenesis, as they are found also in precursor lesions with low-grade dysplasia, such as PanIN
and IPMN with low-grade dysplasia [31].
2.2.2. TP53
The tumor suppressor gene TP53 is located on chromosome 17 and is mutated in a significant
percentage of PC cases, ranging from 50–60% to 80% [32–36]. This so-called “master gene” encodes for
P53, a crucial protein that controls cell growth, metabolism, senescence, DNA repair, and apoptosis
in response to different types of cellular and extracellular processes, such as hypoxia and DNA
damage [37]. The most common alterations affecting TP53 are represented by missense mutations
and base substitutions in the DNA-binding domain, coupled with loss of the wild-type allele. Similar
to KRAS mutations, TP53 alterations are currently considered “undruggable” from a therapeutic
perspective, thus representing another reasonable explanation for PC’s high-mortality rate. Mutations
affecting TP53 represent a late event in the PC carcinogenesis: indeed, they have been found in PanIN
and IPMN with high-grade dysplasia or in the infiltrating component of PC only [31].
2.2.3. CDKN2A
CDKN2A is a tumor suppressor gene located on chromosome 9. It is altered in a several different
types of tumor, and its inactivation is reported in up to 95% of PC variants. The inactivation of this
tumor suppressor can occur following three different processes: (1) intragenic mutations associated
with loss of the second allele (40%); (2) homozygous deletion (40%); (3) promoter hypermethylation
associated with the loss of the second allele (in remaining cases) [38,39]. P16, the protein encoded
by this gene, acts as a mediator of the “retinoblastoma” (RB) signaling pathway. By inhibiting the
phosphorylation of RB, P16 stops the entry of cells into the S phase of the cell cycle. Alterations of
this signaling pathway thus promotes an uncontrolled cell growth and neoplastic progression [40].
Of importance, fluorescence in situ hybridization is a common method for evaluating homozygous
deletion of the CDKN2A locus [41]. Alterations affecting CDKN2A represent a late event in the
oncogenesis of PC [31].
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2.2.4. SMAD4
Alterations of the tumor suppressor gene SMAD4 (also called DPC4), located on chromosome
18, are reported in a variable percentage (30% to 60%) [34–36,42–44]. This gene is inactivated by
homozygous deletion or intragenic mutations matched with loss of the second allele. The protein
encoded by SMAD4 is an effector of the transforming growth factor (TGF)-β signaling pathway.
In normal tissues, this pathway is important in preserving physiological homeostasis; indeed, it
plays a crucial function in the control of cell proliferation. SMAD4 mutations and consequent
perturbations of this pathway leads to a proliferative effect and by the activation of the process of the
epithelial-to-mesenchymal transition (EMT) [45,46]. In this process, cancer cells lose their epithelial
features and acquire a “mesenchymal” phenotype, which is essential for vascular invasion and overall
metastatization. Recent studies have demonstrated that SMAD4 mutations increase the fitness of PC
cells to colonize distant organs, thus characterizing PC cases with widespread metastatization, and
are usually absent in cases in which the disease remains locally aggressive for a relatively long time
during its course [47]. Mutations affecting SMAD4 represent a late event in the oncogenesis of PC: they
have been found rarely in PanIN and IPMN with high-grade dysplasia, most commonly characterizing
only the infiltrating component [31].
2.2.5. Other Mutations
Among less commonly mutated genes, some, such as AT-rich interaction domain 1A (ARID1A)
and TGF-β receptor (R) I, have also been reported in different studies and are defined as “genetic
hills” in the PC landscape. The most important “hill” is represented by the ARID1A gene, located
on chromosome 3. It is a tumor suppressor gene and its mutations are usually associated with poor
prognosis in several types of solid malignancies [34,47]. It encodes for a component of the of SWI/SNF
(BAF) complex, a multi-protein complex with important functions in chromatin remodeling. This
is an epigenetic modulator, which can regulate the gene expression without modifying the DNA
sequence [48]. Mutations affecting ARID1A can result in a profound dysregulation of the chromatin
remodeling mechanism, with important advantages for the proliferation of cancer cells [48,49].
PC molecular landscape is also characterized by complex chromosomal alterations. A recent
whole-genome sequencing based study, conducted by the International Cancer Genome Consortium,
has found 11,868 somatic structural variants at an average of 119 variants per PC case [36]. In this study,
PC has been classified into 4 different subtypes based on structural variations: (1) stable; (2) locally
rearranged; (3) scattered; (4) unstable. Particularly, in the “unstable” subgroup of PC (characterized
by marked genomic instability), tumors showed a significantly increased proportion of breast cancer
gene 1 (BRCA1), BRCA2, and partner and localizer of BRCA2 (PALB2) mutations. As an immediate
consequence, patients who received platinum-based therapy experienced very significant clinical
benefit. At the same time, this study first highlighted the therapeutic potential of PARP-inhibiting
agents, also in PC: this class of drugs, indeed, has recently emerged as a potential targeted therapy in
selected, genetically characterized, cases [49]. In terms of targeted therapy, the BRAF (v-raf murine
sarcoma viral oncogene homolog B1) oncogene may also be mutated in PC, but its prevalence is
less than 2% of all cases [50]. A recent study has shown that PC in older patients (>50 years) were
significantly more likely to harbor genomic alterations in KRAS and SMAD4, whereas BRCA1 and
BRCA2 alterations were more commonly detected in PC from younger patients (<50 years). A higher
frequency of genomic alterations in KRAS, SMAD4 and CDKN2A were found in samples from female
patients, whereas PC in male patients more often exhibited alterations in GNAS [50].
Some variants of PC also exhibit peculiar genetic alterations, not commonly observed in
conventional PDAC. For example, the medullary PC variant often shows microsatellite instability
(MSI), which can be targeted with immunotherapy [50–54]. The colloid PC variant, usually arising
from IPMN, also has an increased rate of MSI and mutations in GNAS, located on chromosome 20,
are also common in this variant [21,55,56]. Lastly, the PC variant with osteoclast-like giant cells is
enriched for mutations in the SERPINA3 oncogene, although its peculiar morphological aspect has
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been mainly linked to its specific inflammatory background rather than its genetic profile, which is
quite overlapping to conventional PC [57].
2.3. Dysregulation of Core Signaling Pathways
Thirteen main individual signaling pathways are currently reported altered in PC
(Table 1) [34,50,58].
Table 1. The most important genetic pathways altered in PC.
Name of the Pathway
Most Important Mutated Gene (s)
Oncogenes Tumor Suppressor
MAPK signaling KRAS
DNA damage control TP53, BRCA1, BRCA2
Control of G1/S Phase transition CDKN2A
TGF-β signaling TGF-βRII SMAD4
Apoptosis CASP10, VCP
Hedgehog signaling SOX3, GLI1, GLI3
Homophilic cell adhesion CDH1, FAT
Integrin signaling ITGA4, ITGA9, LAMA1, LAMA4, LAMA5
JNK signaling MAP4K3, TNF
SWI/SNF ARID1A
Small GTPase signaling RP1
WNT/Notch signaling MYC TSC2
Axon guidance SLIT2, ROBO2
ARID1A, AT-rich interaction domain 1A; CDKN2A, cyclin dependent kinase inhibitor 2A; GTP,
guanosine-5’-triphosphate; ITGA, integrin alpha subunits; KRAS, Kirsten rat sarcoma; LAMA, laminin subunit alpha
1; MAP4K3, mitogen-activated protein kinase kinase kinase 3; SOX, sry-related HMG box; SWI/SNF, switch/sucrose
non-fermentable; TGF, transforming growth factor; TNF, tumor necrosis factor; TP53, tumor protein 53; TSC,
tuberous sclerosis complex; VCP, valosin containing protein.
The first NGS study conducted by Jones and colleagues analyzed a cohort of 24 PC, finding an
average of 63 genetic alterations per case [34]. This study showed that the most common mutations
were base substitution, mainly involving the four PC driver gene KRAS, TP53, CDKN2A and SMAD4.
A significant intra-tumor heterogeneity was also described. Of note, the most important result of
this pioneering investigation was represented by the finding that the vast majority of mutated genes
belonged to 12 so-called “core-signaling pathways”. Such pathways, integrating also the results of
more recent publications, can be summarized as follows: (1) the MAPK signaling pathway, which is
regulated by KRAS GTPase and still remains the most difficult target for tailored treatments; (2) the
DNA damage control, which includes TP53 and represents a crucial event for the acquisition of the
invasive capacities by PC, being a late event during PC carcinogenesis; (3) the regulatory pathway
of G1/S cell phase transition, essential for the preparation of DNA synthesis, with the participation
of P16; (4) the TGF-β signaling pathway, which is mainly regulated by the SMAD family of genes;
(5) the pathway of apoptosis, in which the caspase proteins play a very important role and are of
importance for the proliferation of cancer cells; (6) the hedgehog pathway, recently emerged as a
potential target for precision oncology, which is mainly regulated by GLI3 gene products in PC; (7) the
pathway of homophilic cell adhesion, in which the class of CDH and FAT genes are the most important
effectors; (8) the pathway of integrin signaling, in which the encoded proteins regulate cell-to-cell
adhesion and drive the process of local invasion of cancer cells; (9) the c-Jun N-terminal kinase (JNK)
signaling, which is based on the energy transfer of phosphoryl groups and mainly involves MAP4K3
and tumor necrosis factor (TNF) as most important genes; (10) the pathway belonging to chromatin
remodeler-complexes (SWI/SNF), in which ARID1A is the most commonly mutated gene; (11) the
signaling pathway dependent on small GTPases (KRAS excluded); (12) the Wnt/Notch signaling
pathway, fundamental also in other types of cancer and represented by the MYC and GATA6 genes
as the main regulators; (13) to these pathways, another study has suggested to add a thirteenth,
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represented by the path of the embryonic driving regulators of the axon, which sees as the main
signaling pathway the “so-called” SLIT/ROBO pathway [24,59]. Starting from the manuscript of Jones
and colleagues, all the findings regarding the most important molecular pathway in PC have reinforced
the vision of PC as a very complex disease with several different interactions and with a remarkable
intra-tumor heterogeneity. Tailored therapeutic strategies in PC, based on a single gene only, have also
for these reasons limited success for this patient setting [24]. Very recently, some clinical trials have
initiated new approaches against PC, specifically using signaling pathway inhibitors (Table 2) [58].





















Second Line Palbociclib I NCT03454035
KO-947 Kura Oncology Second Line - I NCT03051035
CDK 4/6 Inhibitors
PD-0332991 Dana Farber Institute Any Gedatolisib I NCT03065062
Palbociclib Pfizer Any Nab-paclitaxel I NCT02501902
KRASG12C Inhibitors











Entrectinib Hoffmann-La Roche Any - II NCT02568267
Larotrectinib Loxo Oncology Second Line - II NCT02576431
ALK, anaplastic lymphoma kinase; CDK, cyclin-dependent kinase; ERK, extracellular signal–regulated kinase;
KRAS, Kirsten rat sarcoma; RTK, receptor tyrosine kinase.
Although the majority of these trials are of phase I, they represent one of the most important
promising strategies of precision medicine for PC.
2.4. Molecularly-Defined PC Subtypes
Of interest is also reporting a recent attempt of classification of PC based on the frequency and
distribution of structural rearrangements. Using data from whole-genome sequencing, Waddell
and colleagues identified four different PC subtypes [36]. Subtype 1 was classified as “stable” and
represented about 1/5 of cases. “Stable” was used to indicate that such neoplasms contained ≤50
structural variation events. Furthermore, this PC class often presented widespread aneuploidy
suggesting defects in cell cycle/mitosis. Mutations of major PC driver genes were similar to the rest of
the cohort. Subtype 2 was classified as “locally rearranged” and represented about 1/3 of all samples.
This subtype presented a significant focal event on one or two chromosomes. About 1/3 of locally
rearranged genomes contained regions of copy number gain that harbored known oncogenes, including
focal amplifications with therapeutic targets (e.g., ERBB2). Another important molecular process
discovered in this PC class was represented by chromothripsis. This process has been more recently
described also in pancreatic neuroendocrine tumors, and causes fragmentation of a chromosome in
many segments with consequent inaccurate reparations [60]. Subtype 3 was called as “scattered”
and comprises, similarly to the “locally rearranged” class, about 1/3 of all cases. This PC subgroup
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presented a moderate range of non-random chromosomal damage and less than 200 structural variation
events. At last, subtype 4 was called “unstable” and included about 15% of all samples. PC of this class
harbored a large number of structural variation events (>200). This significant genomic instability
suggested defects in DNA maintenance, with potential sensitivity to DNA-damaging agent. Of note,
few patients within this group and with mutations affecting BRCA genes demonstrated clinical benefits
from platinum-based therapy.
Several classifications have been also proposed based on mRNA expression analyses of
bulk or microdissected tissues. Overall, when considering the characteristics of neoplastic
cells all three classifications agree on the existence of two major lineages (classical/pancreatic
progenitor and quasimesenchymal/basal-like/squamous) specified by different transcriptional
programs and showing different prognosis and drug sensitivity [61–63]. In particular, the
squamous/basal-like/quasi-mesenchymal lineage is characterized by loss of endodermal origin and
activation of p63 and Dnp63 transcriptional programs. The analysis of bulk tissues also evidenced the
existence of additional subtypes (Immunogenic and ADEX) which can be considered as classical/pp
tumors but heavily infiltrated by non-neoplastic components, particularly leukocytes. Several studies
have shown that a better understanding of the cell autonomous and non-cell autonomous determinants
of molecular subtypes might lead to the design of better therapeutic intervention [64,65]. Along the
same line, transcriptional rather than genetic signatures are being proven predictive of response to
chemotherapy regimen or targeted therapy approaches [66].
3. TME
PC has long been described by pathologists as “a hypertrophic scar with sparse neoplastic
cells”and stromal components may represent up to 85% of the tumor mass in PC, probably the most
“desmoplastic” malignancy, among all solid tumors. PC desmoplastic stroma is a complex environment
composed by both cellular and acellular components, such as cancer associated fibroblasts (CAF),
immune cells (macrophages, neutrophils, myeloid-derived suppressor cells (MDSC), lymphocytes),
and endothelial cells, on one hand, and collagen, fibronectin, and soluble factors (cytokines and
chemokines), on the other (Figure 1). Such distinctive desmoplastic reaction around the tumor tissue
is due to an intense autocrine and paracrine cross-talk between cancer and non-cancer components.
Whether (or, more precisely, under what circumstances) TME represents a friend or a foe in terms of
biological and clinical aggressiveness and response to therapy in PC remains a hotly debated topic.
Indeed, TME elements with putative protumor properties are summarized in Table 3. Given the central
role of TME in PC, understanding the biology behind tumor-stroma interactions (TSI) will be crucial to
develop new therapeutic strategies for PC patients.
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Table 3. Contribution of protumor TME components in PC.
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Endothelial ↑antitumor immune cells ↑OS [74]
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↓E-cadherin
↓patient prognosis [75,76]











Collagen I, IV, V ↑tumor proliferation and EMT ↓patient prognosis [83–87]
Lumican ↑tumor proliferation ↓patient prognosis [88]
Fibronectin ↑EMT













↑tumor proliferation, angiogenesis, CSC properties, ECM disruption
and migration
↓patient prognosis [95–97]









TNF-α ↑tumor proliferation, EMT and migration ↓patient prognosis [107,108]
aPSC, activated pancreatic stellate cells; CAF, cancer associated fibroblasts; CSC, cancer stem cells; DC, dendritic cells; ECM, extracellular matrix; EMT, epithelial mesenchymal transition;
IL, interleukin; M2, macrophages M2 phenotype; MDSC, myeloid-derived suppressor cells; MIF, macrophage migration inhibitor factor; TGF, transforming growth factor; TNF, tumor
necrosis factor; TNM, tumor node metastasis; OS, overall survival; PFS, progression free survival.




Quiescent Pancreatic Stellate Cells (qPSC) are involved in maintenance of pancreatic tissue
architecture and lipid and vitamin A storage; in response to external stimuli (known PC risk factors
(e.g., ethanol and smoking), environmental stress (e.g., hypoperfusion and hypoxia), soluble cellular
factors (e.g., interleukin (IL)-6 and TGF-β) and activation of molecular signaling pathways (e.g.,
Wnt/β-catenin and PI3K)), they skew towards activated PSC (aPSC), acquiring alpha-smooth muscle
actin (α-SMA) expression and enhancing ECM deposition and the release of soluble factors involved
in angiogenesis and EMT. In PC, aPSC represent the most important source of CAF: they represent
the predominant fibroblast cell type in PC stroma and share similar features, including increased
expression of the most important myofibroblastic marker α-SMA and of the CXCL12 cytokine involved
in lymphocyte recruitment [67,70–72,109]. For these reasons, it is quite accepted that aPSC and CAF
represent the same cellular population, even though their classification is still debated and some groups
maintain a distinction between the two cell populations [110,111].
Whether CAF and aPSC exert pro- or anti-tumor activity in PC remains a matter of debate, owing
to opposite lines of experimental evidence. In general, both CAF and aPSC are involved in tumor
proliferation and growth, metastasis and immunity disruption, thereby causing chemoresistance
(Figure 1) [73,112]. For example, Wei and colleagues demonstrated that CAF release CXCL12 which in
turn upregulates the expression of the nuclear matrix attachment region-binding protein SATB-1 in PC
cells; through a reciprocal feedback loop between fibroblasts and tumor cells, SATB-1 is involved in
maintenance of CAF features (i.e., α-SMA, fibroblast activation protein and CXCL12) and gemcitabine
resistance [113]. Chemoresistance is also induced by hypoxic conditions, as revealed by multiple
studies in which the authors demonstrated that stroma depletion upregulates intratumor perfusion and
gemcitabine accumulation at the tumor site, thus promoting cytotoxicity and prolonging survival [114].
Another mechanism involved in gemcitabine-resistance is linked to the decrease of aPSC-mediated
apoptosis, as demonstrated by Liu and coworkers. In the same paper, the authors also demonstrated
the key role of another soluble factor, TGF-β1, in TSI: indeed, the TGF-β1 inhibitor SB525334 partially
blocks aPSC and tumor cells viability and aPSC-dependent invasion [115]. A further signaling pathway
involved in affecting the interactions between PSC and pancreatic tumor cells is the MAPK cascade, as
very recently demonstrated by Amrutkar and collaborators. Indeed, activation of ERK1/2 in PC cells,
mediated by fibronectin aPSC-released, is involved in gemcitabine resistance: consistently, inhibition
of aPSC-released fibronectin or ERK signaling may counteract chemoresistance and deserves further
investigation as a potential therapeutic strategy [69]. In clinical PC series, CAF activation appears
to correlate with reduced OS: indeed, produced by CAF promote tumor cell invasion and a high
proportion of CAF in primary tumors correlates with nodal and distant metastases and a high lymph
node ratio [116].
On the other hand, in other reports low levels of α-SMA+ myofibroblasts correlated with poor
survival of PC patients, thereby leading to the hypothesis that fibrosis constitutes a “protective” TME,
rather than a tumor promoter. Alpha-SMA+ myofibroblasts knock-out mice display multiple adverse
outcomes, such as reduced immunosurveillance and gemcitabine resistance; chemoresistance could be
reverted by a combination of gemcitabine plus anti-CTLA-4 treatment, which resulted in increased
animal survival [117].
Endothelial Cells
Another important element in PC stroma is represented by endothelial cells and the mutual
influence between endothelial cells and PC microenvironment is now well established. Indeed, the
mere presence of conditioned medium derived from hypoxic PSC increases angiogenesis by inducing
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endothelial cells proliferation and migration in vitro and in vivo [118]. Conversely, conditioned
medium derived from PC cells reduces endothelial cells proliferation [119]. However, the reciprocal
influence between these cells on their growth is not yet defined: indeed, Craven and her collaborators
showed that PC cells promote endothelial cells expansion. This group has recently demonstrated that
the concomitant inhibition of TGF-β1R and janus kinase (JAK) 2 suppresses the mitogenic effects exerted
by both endothelial and PC cells [120]. The endothelial cells surface marker, CD31, is significantly
associated with better prognosis and improved overall survival (OS) in PC patients. Indeed, tumors,
which express high levels of CD31, are associated with higher infiltration of anti-cancer immune cells
(e.g., CD8+ and CD4+ T cells) [74]. Moreover, CD31 correlates with SMAD4 expression. Therefore,
it is not surprising that SMAD4, frequently mutated in PC tissue, is associated with the number of
endothelial cells in PC [120].
3.1.2. Immune Cells
In PC, cellular stromal components are also characterized by different immune cells which
influence each other with endothelial cells to define an immunosuppressive TME.
Macrophages
Macrophages infiltrate PC attracted by vascular endothelial growth factor (VEGF)/VEGFR2
interactions [121] and affect its biological properties and clinical behavior. When polarized towards
an M1 phenotype (HLA-DR+ and CD11c+), they exhibit pro-inflammatory properties; conversely,
M2-polarized macrophages express CD163 and CD204 and exert tumor-promoting functions [108,122].
In PC TME hypoxic conditions and aPSC-derived cytokines, such as IL-10 and IL-13, polarize
macrophages towards a M2, pro-tumor phenotype [123,124]. In addition, the expression of the toll-like
receptor 4 on M2 macrophages promotes a vicious circle, stimulating further IL-10 release by tumor
cells and promoting EMT through E-cadherin inhibition and Snail and vimentin upregulation [75].
In line with preclinical evidence, clinical data also confirm a dominant role of these cell populations
within the PC immune landscape: indeed, macrophages are more represented in cancer tissue as
compared to healthy pancreas, and their accumulation starts at the level of early stage lesions (PanIN)
and increases during invasive cancer transformation [125]. In particular, macrophages exert an active
role in conferring an aggressive behavior to primary PC through the regulation of the TGF-β [126].
Consistently, M2 populations represent a negative prognostic factor [76].
Neutrophils
Similar to macrophages, neutrophils represent another group of myeloid-derived circulating cells
belonging to innate immunity. Despite their role in TME is still debate, the increasing knowledge of this
cell type led to differentiate tumor associated neutrophils in N1 (with anti-tumor properties) and N2
(with pro-tumor properties), according with the type of cytotoxicity exerted and the ability to activate
different immune cells [127]. Particular interest is actually attributed to neutrophil-to-lymphocyte
ratio (NLR) as a prognostic biomarker in PC. In a recent metanalysis, Zhou and collaborators reported
that patients with low NLR had significant smaller tumor size, longer OS and disease-free survival
(DFS) as compared to high NLR patients [128]. Furthermore, the involvement of neutrophils in
chemoresistance was recently investigated. Indeed, the combined blockade of CXCR2+ neutrophils
and CCR2+ macrophages results in an increased antitumor immune response and response to the
chemotherapy treatment with the FOLFIRINOX regimen, due to the reduction of infiltrating myeloid
cells in the tumor [77].
Lymphocytes
Among immune cells, T lymphocytes are the most represented population and significantly
influences the clinical outcome of PC patients [129]. According to the expression of specific surface
markers, CD3+ T cells are classified in T helper CD4+, Treg CD4+/CD25+/Forkhead box P3 (Foxp3,
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and cytotoxic CD8+ [130]. CD4+ T cells mainly activate innate and acquired immunity, thus it is
not surprising that their levels are lower in tumor tissue and peripheral blood of PC patients, as
compared to healthy subjects; consistently, their infiltration is correlated with better OS [131,132]. On
the other hand, in PC pro-tumor Th2 CD4+ (GATA3+) sub-populations are more represented than
the tumor-killing Th1 (T-bet+) and their levels correlate with poor prognosis [133,134]. Tassi and her
group indeed showed a potential benefit of immune reprogramming strategies aimed at reverting the
predominant Th2 into a Th1 T cell phenotype preclinically, although clinical evidence of potential
effectiveness is currently lacking [135]. Another subset of CD4+ cells characterized by the production
of IL-17 (Th17) has been shown to play a pro-tumor role in PC, where both tumor-infiltrating Th17
CD4+ cells and circulating levels of Il-17 and IL-23 correlated with advanced stage and worse OS [78].
The well characterized Treg sub-population of immune cells contribute to an immunosuppressive
TME by promoting CTLA-4 expression and TGF-β release [79,136]. In PC stroma the Treg population
profoundly suppresses the activity of antitumor immune cells (i.e., CD4+, CD8+, macrophages and
dendritic cells—DC) [79]. According to their tumor-promoting role, high levels of Treg cells are detected
at the PC tumor site and circulating in the bloodstream, as compared to control subjects [137,138].
However, recent new data suggest that through their interactions with fibroblasts in PC TME, Tregs
may actually counteract tumor development: indeed, it has been demonstrated that Treg depletion
promotes pancreatic carcinogenesis, as a result of CAF activation and immunosuppressive myeloid
infiltration [139].
CD8+ are cytotoxic T cells which may curtail the proliferation of tumor cells through two
mechanisms: macrophages and interferon (IFN)-γ, activation [140]. Consistent with the ability of
PC to evade tumor immunoediting, CD8+ T cells are rarely detectable in PC and their presence
is associated with better prognosis (Figure 1) [141]. During tumor progression, PC evades CD8+
cytotoxicity, by causing both direct CD8+ aggregation in the desmoplastic tissue and indirect CD8+
inactivation through TGF-β secretion [142]. TGF-β release by PC cells in turn inhibits the transcription
of CTL cytotoxic genes: perforin, granzyme A, granzyme B, Fas ligand, and IFN-γ, in vitro; these
data support the hypothesis that TGF-β targeting could restore cytotoxic response involved in in vivo
tumor clearance [143].
MDSC
MDSC are a heterogeneous group of immature cells classified in polymorphonuclear granulocytic
MDSC and mononuclear monocytic MDSC, although they lack specific surface markers [144]. MDSC
are represented in both human peripheral blood and TME and are involved in tumor growth, invasion
and angiogenesis, through their activity on immune cells: for example, they promote the switch
from M1 to M2 macrophage phenotype, promote Treg expansion and suppress natural killer (NK),
CD4+, and CD8+ cells [81,82]. Indeed, in PC the levels of intratumor MDSC correlate with circulating
Treg, but not with infiltrating CD8+ [145,146]. Moreover, circulating MDSC levels in PC patients are
higher than in control subjects and increase upon disease progression [80]. Due to their contribution
in promoting an immunosuppressive TME, blockade of the interactions between cancer cells and
MDSC could improve clinical outcome by reactivating CD8+ cytotoxic activities. Baine and coworkers
indeed demonstrated that the inhibition of tumor-derived granulocyte-macrophage colony-stimulating
factor (GM-CSF, a cytokine highly expressed in PC and involved in disrupting antigen-specific T cells)
prevents MDSC recruitment and tumor development [147].
DC
Antigen-presenting DC cells exert their effects in antitumor response mainly through
MHC-mediated activation of CD4+ and CD8+ T cells [148]. Due to DC role in patrolling tissues
to respond to danger stimuli, cancer cells develop strategies to evade immunosurveillance by blocking
DC maturation and function; indeed, DC are rarely detected in PC TME [149,150]. Levels of both
circulating and infiltrating DC correlates with better prognosis in both resectable and unresectable PC;
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furthermore, Fukunaka and coworkers reported a positive correlation between DC and CD4+/CD8+
tumor infiltration and an improved patient prognosis [132,151,152]. DC-based vaccination has
been shown to gemcitabine’s therapeutic efficacy in the Panc02 poorly immunogenic murine tumor
model [153]. Although preliminary clinical results with DC-based vaccination have shown tolerability
and immunogenicity, clinical efficacy remains to be demonstrated [154,155].
3.2. Acellular Components
3.2.1. ECM
PC is histologically characterized by the abundance of ECM which, in addition to mechanical
support, influences both the cellular and molecular composition of pancreatic stroma [156]. This
three-dimensional acellular portion is composed by fibrous proteins (e.g., collagen, fibronectin, laminin,
proteoglycans (e.g., decorin, biglycan, and lumican)) and water, and represents a dynamic structure
in continuous remodeling, especially during tumor progression [157]. In normal pancreatic tissue,
PSC regulate ECM turnover through the synthesis and metalloproteinase (MMP)-2/MMP-9-dependent
degradation of ECM proteins [158,159]. Since PSC activation is an early event during the neoplastic
transformation, it is not surprising that PSC and PC cells bidirectionally influence ECM dynamics
to sustain cancer progression: indeed, aPSC enhance ECM proteins production and remodeling,
hence providing a more favorable microenvironment for tumor cell growth [160]. The excessive
PSC-dependent ECM proteins deposition also contributes to increase tissue hypoxia, which could
explain the biological mechanism behind the failure of antiangiogenic therapies in PC [119].
Collagens
Collagens are one the best characterized and most abundant components of PC’s ECM and 28 types
with at least a triple-helical domain are currently identified [161]. In TME, PC cells intensively interact
with interstitial collagens and these connections significantly foster the pro-tumorigenic features, such
as EMT and invasion, through both integrin-dependent and -independent signaling [162]. Indeed,
collagens can either bind integrin receptors or the tyrosine kinase discoidin receptor 1 (DDR1) expressed
by PC cells. The combination of different α and β subunit heterodimers allows integrin receptors to
bind different types of collagens, in order to activate several intracellular signaling pathways. The
canonical integrin-dependent biological mechanisms comprise focal adhesion kinase-mediated cell
migration and EMT through downregulation of E-cadherin [83,84]. On the other hand, binding of
collagen to DDR1 promotes invadopodia formation and MMP-2/MMP-9 expression [163,164]. Recent
evidence has demonstrated that different collagen types can play contrasting roles in tumor. Collagens
I, IV and V are involved in tumor progression by affecting adhesion, migration and cell viability
and their levels increase and correlate with cancer stage and decreased patients’ survival. Ohlund
and collaborators demonstrated that collagen IV colocalizes with integrin receptors on cancer cell
surface and their interaction maintains cell proliferation and avoids apoptosis [85]. Similar effects are
exerted by collagen V, which has been identified as a tumor promoter in PC: indeed, Berchtold and
coworkers showed that PSC release collagen type V, which promotes invasion and proliferation of PC
cells [86]. On the other hand, collagen XV decreases during PC progression, consistent with its role in
hindering protumor features [165]. These controversial roles played by different types of collagens
reflect the plasticity of ECM: indeed, the collagens architecture is continuously modified during cancer
progression in order to favor the acquisition of a more aggressive behavior (Figure 1). In that respect,
collagens mainly contribute to provide mechanical cues and ECM stiffness, which increase resistance
to conventional treatments [87].
Proteoglycans
Many of the ECM-characterizing proteins are glycoproteins, a large group of molecules divided
in four families, according to cellular and subcellular localization, genetic homology and protein
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activity [166]. Proteoglycans are heavily glycosylated proteins and their pattern of N- or O- glycosylation
fluctuates during neoplastic transformation, in order to promote cell proliferation, angiogenesis and
immune response [167]. Among proteoglycans, decorin, biglycan, and lumican are all small leucine-rich
proteoglycan and the most important in PC [167]. Decorin acts as a monomer Zn2+ metalloprotein and
is the first proteoglycan shown to be involved in the regulation of cell growth, by inhibiting TGF-β,
ERBB2 dimerization and receptor tyrosine kinase signaling [168–172]. Since it mainly displays tumor
suppressive properties, it is not surprising that low levels of its expression are detected in the stroma
of many solid tumors, including PC, and its production is suppressed at a transcriptional level by
TNF-α [166,173]. Köninger and coworker demonstrated that decorin is mostly released by PSC rather
than by tumor cells in PC; however, cancer cells are sensitive to the decorin-dependent anti-tumor
activity of chemotherapeutic drug carboplatin [174]. Biglycan shares > 65% of homology with decorin,
and consistently also biglycan is able to bind and inactivate TGF-β [175]. More specifically, Weber and
his collaborators showed that biglycan is expressed by fibroblasts in PC and overexpressed by cancer
cells in response to TGF-β. Moreover, as a compensative host defense mechanism, biglycan affects cell
growth in a TGF-β-independent manner, by inducing the cyclin-dependent kinase inhibitor p27 and a
consequent cell cycle arrest [175]. Yamamoto and coworkers investigated the role of lumican in PC
progression and demonstrated that lumican-transfected PANC-1 cells display a hyperactivated ERK
pathway, which stimulates cell growth and lowers invasive ability [88]. Li and colleagues correlated the
expression of lumican with prognosis in 131 untreated PC patients undergoing surgery and observed
that patients with higher levels of this proteoglycan had significantly increased OS after tumor resection,
as compared to those with low lumican expression levels (p = 0.0006). In the same paper, they also
demonstrated that lumican increases apoptotic signals via hypoxia-inducible factor (HIF)1-α blockade
in PC cell lines in vitro [176]. Hence, the role of lumican in PC is not yet well clarified, probably
due to differential glycosylation pattern of lumican between the experimental conditions of different
analyses [88].
Fibronectin
Fibronectin is the most abundant acellular component within PC tumor stroma and is mainly
produced by aPSC [159,177,178]. Fibronectin is recognized by integrins family members which
represent the best characterized fibronectin receptors; through this binding, different processes such as
proliferation, migration, adhesion and survival, are modulated [178]. An anti-β1 integrin antibody
profoundly modifies pancreatic TME, hence counteracting fibronectin polymerization and fibrillar
collagen I formation in PANC 1/3 T3 spheroids [179]. Moreover, Cortes and his colleagues demonstrated
that tamoxifen treatment reduces the hypoxic response of PSC, leading not only to a reduction of
fibronectin alignment and thickness, which are associated with lower cellular invasion, but also to an
increase of fibronectin protein expression in in vitro experiments [180]. In PC, fibronectin production
is related to the activation of the NF-κB pathway: Jagadeeshan and coworkers demonstrated that
p21-activated kinase 1, a serine/threonine kinase significantly upregulated in PC as compared to
normal tissue, stimulates fibronectin production by promoting the direct NF-κB binding to fibronectin
promoter [181]. Fibronectin upregulation in PC is associated with advanced clinicopathological stage
and tumor aggressiveness [177]. Moreover, fibronectin-induced EMT correlates with poor OS in
surgically resected PC patients [89]. Currently, the use of multi-gene expression profile datasets and
meta-analyses has led to the identification of fibronectin as one of ten hubs that may be involved in
PC progression and pathogenesis [182]. Along these lines, focal adhesion kinase (FAK) activation
downstream of integrin binding to fibronectin and collagens correlates with high levels of fibrosis
and poor CD+ cytotoxic T cell infiltration in PC; FAK inhibition limited tumor progression, markedly
reduced tumor fibrosis, decreased the numbers of tumor-infiltrating immunosuppressive cells, and
rendered the previously unresponsive KPC mouse model responsive to T cell immunotherapy and
programmed cell death protein (PD)-1 antagonists. [183].
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3.2.2. Cytokines
Cytokines are a family of soluble factors, classified into growth factors, chemokines, angiogenic
factors and interferons and involved in tumor immune-landscape, by exerting pro- (IL-1β, IL-6,
IL-8, and macrophage migration inhibitory factor—MIF) and anti-inflammatory (IL-10 and TGF-β)
functions [184]. In TME, several cell types (e.g., immune, stromal, and tumor cells) release cytokines,
involved in pleiotropic biological mechanisms through the binding to their specific cognate receptors
in an autocrine and paracrine fashion. More in detail, cytokines affect the dynamic and complex
immune network in TME, promoting PC immune-escape, PC progression, and drug response [184].
Evidence demonstrates that circulating pro-inflammatory cytokines are elevated in PC patients, as
compared to healthy subjects, induce the PC cachexia clinical syndrome, and associate with clinical
outcome, hence rendering these soluble factors new potential prognostic biomarkers and therapeutic
targets (Figure 1) [185,186]. However, the role played by cytokines is often controversial, as the same
factor (i.e., TNF-α) can be both a tumor promoter or a suppressor; thus, a recent systematic review
suggested that considering a set of cytokines, rather than a single one, could be a more exhaustive
and comprehensive approach [187]. Here, we summarize the biological implications of the most
investigated cytokines potentially involved in PC disease course and prognosis.
IL-1β
IL-1β is a pro-inflammatory cytokine synthetized by monocytes, tissue macrophages, and PC
cells; through the binding to the type 1 IL-1R, shared with IL-1α, the cleaved form of IL-1β activates
NF-κB in PC cells [188]. Etoposide-resistant PC cell lines display elevated IL-1β production and NF-κB
activity; blocking IL-1β signaling with an anti-IL-1R(I) antibody results in decreased NF-κB activity and
restored chemosensitivity. Consistently, IL-1β produced by resistant A818-4 and PancTu-1 cell lines
confers chemoresistance to the otherwise chemosensitive PT45-P1 cells, by enhancing the NF-κB [189].
IL-1β is also involved in promoting tumor aggressiveness by directly modulating the migration ability
of both inflammatory and tumor cells through the regulation of the integrin superfamily. Indeed, IL-1β
reduced integrin signaling in PC cell lines via JNK activation: JNK silencing counteracts IL-1β mediated
vinculin and α5-integrin blockade [190]. Moreover, Schmid and his colleagues demonstrated that the
recruitment and adhesion of myeloid cells is increased by IL-1β-induced integrin α4β1 activity [90]. In
PC patients, IL-1β levels correlated with poor progression free survival (PFS; p = 0.056), especially
when combined with high IL-6 levels (p < 0.001; see also below) [91].
IL-6
IL-6 is another proinflammatory cytokine, which activates JAK 2 and signal transducers and
activators of transcription (STAT)1 and STAT3, through the IL-6 presentation to the signal-transducer
gp130 by IL-6 receptor [191]. Once activated, JAK stimulates signaling through downstream pathways
(MAPK, PI3K and STAT) involved in the promotion of cell cycle progression and proliferation.
Furthermore, IL-6 is involved in PSC-mediated EMT in PC cells, as demonstrated by the reversion of
STAT3-dependent EMT after either anti-IL-6 antibody treatment or STAT3 inhibition [92]. IL-6 may
additionally contribute to the regulation of angiogenesis and metastatization, through the modulation
of multiple soluble players. Indeed, IL-6 promotes the expression of angiogenesis-related genes such as
VEGF, neuropilin (NRP)-1 and IL-10 [93]. Moreover, IL-6, IL-10, TGF-β, and VEGF together orchestrate
the inhibition of dendropoiesis, thus shaping an immunosuppressive TME [94]. In PC patients, IL-6
levels are higher in metastatic disease than in locally advanced tumors (p = 0.0001) [94] and IL-6
released by myeloid cells in TME activates STAT3 signaling in PC cells, hence affecting poor patient’s
outcome [192].
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IL-8
Initially identified as a neutrophil-activating peptide, IL-8 is now a well-established
proinflammatory chemokine, which signals through the binding to the CXCR1/2 receptors, thereby
activating several G-protein-mediated signaling cascades involved in conferring several pro-tumoral
properties to cancer cells [193]. Indeed, due to the presence of their receptors in several TME cell
types (e.g., neutrophils, macrophages and endothelial cells), IL-8 regulates a plethora of mechanisms,
such as cell proliferation and migration, angiogenesis, EMT and immune-escape [95]. PC cell lines
release higher levels of IL-8 in culture medium, as compared to non-transformed HPDE cells; moreover,
exogenous IL-8 increases the expression of the pro-angiogenic factor VEGF and its receptor NRP-2
and the levels of ERK phosphorylation, directly promoting tumor angiogenesis and cell proliferation,
respectively [96]. Another group described a model in which stromal and tumor cells influence each
other to enhance invasion and angiogenesis: in co-culture conditions, cancer cells stimulate fibroblasts
to release higher levels of CXCL12 which, in turn, upregulates PC cell-derived IL-8 [194]. IL-8 is
also involved in promoting ECM remodeling through MMP-2 and MMP-9 production [195]. The
IL-8/CXCR1 axis is associated with the acquisition of CSC markers, such as CD44 and CD133, and
functional abilities and correlates with lymph-node metastasis (LNM) (p = 0.012) and shorter OS in
PC patients (p < 0.001) [97]. Furthermore, Chen and colleagues showed that PC patients express
significantly higher IL-8 levels as compared to those with pancreatitis, in both tumor tissues and
blood [196].
MIF
Another pleiotropic pro-inflammatory cytokine often overexpressed in PC is MIF. Although
MIF was initially identified as a specific product of activated T lymphocytes, it is currently known
that macrophages represent the main source of this soluble factor: TNF-α activation regulates MIF
production and viceversa in an auto-amplification loop [197]. MIF interacts with the CD74 receptor,
although complete activation requires the recruitment of different co-receptors, such as CD44 or CXCRs
(e.g., CXCR2, CXCR4) [198]. MIF exerts its oncogenic role in PC through the downregulation of
E-cadherin and the stimulation of vimentin and Zinc finger E-box-binding homeobox 1/2 production,
hence causing EMT. Moreover, MIF-promoted PC aggressiveness is associated with increased resistance
to gemcitabine treatment [98]. Recently, the detection of higher levels of MIF in PC tissue as compared
to normal tissue increased the scientific interest in studying MIF as a new potential therapeutic target:
MIF-overexpressing PC are more aggressive and result in poor OS [98,99]. Consistently, in vitro
experiments demonstrated that the MIF post-transcriptional silencing could lead to PC regression
through the induction of apoptosis and cell cycle arrest [199].
IL-10
Monocytes, macrophages, Th2 CD4+ T cells and activated B cells are the main source of IL-10
production in TME. The IL-10R1 is involved in the activation of specific IL-10 functions and the
heterodimerization of IL-10R1 and IL-10R2 chains is required for outside-in cell signaling [200].
As an inhibitor of inflammatory responses, IL-10 counteracts the productions of proinflammatory
cytokines (e.g., IFN-γ, IL-1β, and IL-6) from different cell types and DC maturation by blocking
IL-12 expression [201]. IL-10 inhibits CD4+ T-cell response induced by mesothelin, an immunogen
involved in promoting metastasis and tumor proliferation and a potential therapeutic target in PC [100].
Consistently, blocking IL-10 partially restores mesothelin-CAR T-cell activity [202]. IL-10 levels are
increased in PC patients, as compared to healthy subjects, and correlate with poor survival of PC
patients [101,102].
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TGF-β
TGF-β plays an essential, but also complex and controversial, role in PC. TGF-β maintains
homeostasis in normal tissue; however, being genetically unstable entities, cancer cells have the capacity
to corrupt this suppressive influence. As a consequence, through the binding to the TGF-βRI and
TGF-βRII heterotetrameric complexes, pathological forms of TGF-β signaling promote tumor growth
and metastasis by activating downstream canonical Smad-dependent, as well as Smad-independent,
intracellular pathways [203–205]. Activated phospho-Smad translocates into the nucleus, where
it binds Smad-binding elements and transactivates TGF-β-dependent genes; non-Smad dependent
signaling, on the other hand, mainly promotes activation of the MAPK pathway through RAS [206].
Regardless of the activated signaling, TGF-β acts as an EMT inducer [103]. Ellenrieder and collaborators
demonstrated that MEK inhibition reduces TGF-β-dependent EMT and PC cells migration in KRAS
mutant contexts [207]. TGF-β is also involved in modulating immune response against cancer cells:
while DC stimulate CD8+ differentiation in co-culture with PC cells, TGF-β blockade improves antigen
specific response and decreases T cells apoptosis; as a consequence, DC vaccination in combination
with TGF-β blockade results in increased DFS in murine tumor models [104]. In PC, TGF-β levels
correlate with clinical outcome and different groups demonstrated that PC patients with high levels of
soluble TGF-β have a worse prognosis, as compared to those with low levels [105,106].
TNF-α
Similar to TGF-β, TNF-α plays a controversial role in PC stage progression and therapeutic
response. Indeed, TNF-α exerts its activity as both a pro-tumoral and an anti-tumoral soluble
factor [208]. This dual role is mainly due to the presence of two different receptors, TNFR1 and TNFR2,
associated with pro-inflammatory and anti-inflammatory signaling, respectively [209]. As a type II
transmembrane protein, TNF-α can bind both TNFR1 and TNFR2, whereas as the soluble form derived
from proteolytic cleavage is able to activate TNFR1 exclusively [209,210]. While the ubiquitously
expressed TNFR1 is mainly involved in apoptotic signaling, the role of TNFR2, mainly expressed on
immune cells, is poorly understood [211]. PC cells-derived TNF-α enhances the tumor cell growth
and invasiveness both in vitro and in vivo [107]. M1 macrophages also induce matrix remodeling
through EMT in a TNF-α-dependent manner, highlighting the importance of TNF-α as a mediator in
pancreatic TME [108]. The levels of TNF-α are higher in serum derived from PC patients, as compared
to chronic pancreatitis or healthy patients [212]. However, gemcitabine treatment upregulates TNF-α
production, resulting in a potent antitumor activity [213]. TNF-α-dependent anti-tumoral activity
is limited by NF-κB activation, which can be overcome by the combination between gene therapy
through an adenoviral vector-expressing TNF-α and nafamostat mesilate, a NF-κB inhibitor which
upregulates apoptosis both in in vitro and in vivo [214].
4. Current Treatment Standard of Care and Novel Therapeutic Strategies
The overall five-year survival rate for PC patients remains below 10% (all stages included) and
although median OS in advanced disease has improved with modern chemotherapy it remains below
one year [2]. Approximately 80% of PC patients presents with surgically unresectable or metastatic
cancer at diagnosis and among resected patients most will recur with metastatic disease within 3
years from surgery. Standard treatment strategies usually become rapidly ineffective, due to the
early development of drug resistance; the cornerstone of PC treatment is conventional cytotoxic
chemotherapy, and no predictive biomarkers are currently available to select patients for targeted
anti-cancer treatments or immunotherapy. Thus, novel therapeutic approaches are urgently needed to
improve the dismal prognosis of PC patients.
So far, results from clinical trials testing agents targeting cell autonomous signaling aberrations
and angiogenesis have been quite disappointing in PC. Clinical trials investigating inhibitors of the
EGFR family of receptors, of the MAPK and of the Hedgehog signaling pathways have failed to
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demonstrate an improvement in OS in PC patients [215–217]. Similarly, targeting the VEGF/VEGFR
axis alone or in combination with an anti-EGFR, have also met with little clinical success; nevertheless, a
small randomized phase II trial did demonstrate potential advantages for the multikinase angiogenesis
inhibitor sunitinib in the first-line maintenance setting [218,219].
So far, alterations in the DNA damage repair machinery appear to be the most promising target(s)
in PC [220]. Five to 15% of PC are characterized by either somatic or germline BRCA mutations and
several case studies reported responses to poly-ADP-ribose-polymerase (PARP) inhibitors [221,222].
While a phase II trial of veliparib failed to demonstrate increased response in PC patients previously
treated with chemotherapy, maintenance therapy with olaparib after a platinum-containing 1st line
regimen prolonged OS in patients with non-progressing PC patients with germline BRCA1/2 mutations
in the phase III trial POLO; olaparib is thus the first PARP inhibitor being granted approval by United
States Food and Drug Administration and European Medicines Agency for the treatment of advanced
PC [49,223]. Additional trials are ongoing to evaluate combination therapy with PARP inhibitors and
chemotherapy or other targeted therapy (NCT01489865, NCT0158805). Similarly, a variable proportion
of PC patients, whose tumors are characterized by defective mismatch DNA repair machinery and
microsatellite instability (MSI-H), appears to experience prolonged responses to immune checkpoint
inhibition by anti-PD1 antibodies [224].
More recently, attempts at modulating TSI with agents targeting different TME components, have
also failed: pegvorhyaluronidase alfa, an agent targeting tumor hyaluronan, napabucasin, an agent
targeting cancer cell stemness, recombinant pegylated IL-10, and a combination of anti-CTLA-4 and
anti-PD-L1 antibodies have all recently shown lack of efficacy in clinical trials in advanced PC patients.
The largest effort of integrated genomic analysis in understanding the molecular pathology of PC
has recently confirmed the TGF-β as the most recurrently mutated signal transduction pathway in
PC [63]. The therapeutic efficacy of the TGF-β canonical Smad-dependent pathway inhibition by using
the small molecule selective inhibitor of the TGF-βRI LY2109761 (Lilly, Indianapolis, USA) was initially
demonstrated in preclinical models of PC [225]. Moreover, the role of a unique Smad-independent
TGF-β pathway represented by the TGF-β activated kinase 1 (TAK1) was dissected in PC [226]. This
serine/threonine kinase has a critical role in sustaining resistance to chemo- and radiotherapy in
PC, by integrating signals from various cytokines and controlling, in turn, the activation of different
transcription factors, including NF-κB [227–229]. More recently, a fundamental role of TAK1 was
demonstrated towards PC chemoresistance through the kinase-independent modulation of two
transcriptional regulators emerging as central determinants of malignancy in this disease, namely
the transcriptional regulator yes associated protein (YAP) and the transcriptional coactivator with a
PDZ-binding domain (TAZ) [230]. In light of these observations, TGF-β signaling represents a key
target for personalized treatment of PC. Different therapeutic strategies have been developed and
demonstrated efficacy in several preclinical and clinical trials in PC. Among the approaches used
to target TGF-β, it is worth to mention trabedersen (AP12009), a TGF-βII antisense RNA molecule,
which inhibits proliferation and migration of human PC cells and reduces growth and metastasis
in human PC orthotopic mouse models [231]. In addition, a trabedersen phase I dose-escalation
trial is ongoing in advanced PC patients (NCT00844064). Soluble TGF-βII was also used as another
therapeutic strategy to inhibit of TGF-β binding to cellular TGF-βR in human PC cells, thereby
suppressing tumor growth, angiogenesis and migratory capability of PC [232,233]. In addition, a phase
I/II trial is ongoing in advanced solid tumors, including PC, with the anti- TGF-β antibody NIS793,
as single agent or in combination with anti-PD-L1 (NCT02947165). Among TGF-β inhibitors acting
at the intracellular signaling level, inhibitors of TGF-βRI kinase (i.e., SD208, SD093 and LY580276)
significantly reduced the aggressiveness of PC cells in preclinical models. In particular, LY580276
is an ATP-competitive inhibitor of the TGF-βRI/ALK5 shown to arrest EMT and migration in PC
cells [234,235]. A multi-center, open-label, phase Ib clinical trial is ongoing to evaluate the safety,
tolerability, and exploratory efficacy of vactosertib (TEW-7197)—a small molecule inhibitor of TGF-βRI
kinase—in combination with FOLFOX second-line chemotherapy in patients with metastatic PC
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after first-line gemcitabine and nab-paclitaxel (MP-PDAC-01, NCT03666832 [236]. The inhibitor of
TGF-βRI/II kinase LY2109761 demonstrated to reduce tumor growth, metastasis and survival in
combination with chemotherapy in an orthotopic murine model of advanced PC [225]. Despite the
great number of TGF-βR inhibitors developed, only a few of them progressed to clinical investigations
mainly due to relevant cardiac adverse events in animals. Compared to others small molecule inhibitors,
galunisertib (LY2157299 monohydrate), an oral small molecule inhibitor of the TGF-βRI kinase that
specifically downregulates the phosphorylation of Smad2, has demonstrated a reduced cardiovascular
toxicity profile in preclinical models and it was the first-in-class to start its clinical development in
PC patients [237]. The phase Ib/randomized phase II, double-blind trial in patients with advanced or
unresectable PC, H9H-MC-JBAJ, demonstrated that the combination of galunisertib and gemcitabine
improved OS versus gemcitabine monotherapy with an expected manageable toxicity [238]. Based on
these positive results, the phase I clinical trial I8X-MC-JECA has been designed and is ongoing in PC
patients, to test the safety of the next generation small TGF-βRI inhibitor LY3200882, in combination
with the most recent standard first-line chemotherapy, gemcitabine and nab-paclitaxel (NCT02937272).
Translational studies have been conducted to measure plasma proteins and miRNA markers at baseline
and during treatment in patients enrolled in the H9H-MC-JBAJ study [239]. Predictive markers,
useful to select patients who may benefit more from TGF-βR inhibition, have been identified. In
particular, macrophage inflammatory protein (MIP)-1-α (a proinflammatory cytokine involved in
the recruitment of monocytes and macrophages) and INFγ-induced protein (IP)-10 (involved in the
recruitment of Treg) were two of the four most significant predictive biomarkers for chemoresistance
in the population receiving single agent gemcitabine (for MIP-1-α mOS 95% CI high vs. low, 3.6
(2.5–4.0) vs. 10.1 (7.2–17.0) months, HR 95% CI = 3.93 (2.13–7.22) p < 0.01; for IP-10 mOS 95% CI high
vs. low, 3.6 (2.5–7.7) vs. 12.5 (7.1–17.0) months, HR 95% CI = 2.78 (1.55–4.99) p < 0.001) [240]. On the
contrary, treatment with galunisertib demonstrated to dramatically revert this resistance as MIP-1-α
and IP-10 were the most significant positive predictive biomarkers for the combination of this agent
with chemotherapy (for MIP-1-α mOS 95%CI galunisertib + gemcitabine vs. gemcitabine, 9.2 (5.5–12.4)
vs. 3.6 (2.5–4.0) months, HR 95% CI = 0.38 (0.22–0.66) p < 0.01; for IP-10, 10.9 (5.5–12.4) vs. 3.6 (2.5–4.0)
months, HR 95% CI = 0.4 (0.23–0.67) p < 0.0015) [239]. These results suggested an involvement of
the immune system in the response of PC to galunisertib. Unfortunately, results from clinical trials
using cancer vaccines or immune-checkpoint inhibitors (anti-CTLA4 and anti-PD-L1) in PC have been
disappointing so far, thus immunotherapy remains a therapeutic challenge in PC patients [241–244].
The challenge for these approaches resides in the fact that, unlike melanoma, PC is characterized
by a highly immune-suppressive microenvironment with a very low number of effector T cells. For
this reason, research is moving towards the use of microenvironment re-educators, such as TGF-β
inhibitors, in combination with checkpoint inhibitors, as a strategy for “immune-excluded” tumors,
aiming to converting a non-immunologic tumor into an immune-responsive disease. Preclinical
data from PC mouse models demonstrated that silencing of TGF-βRI induced a recruitment of
CD8+ lymphocytes around PC [245]. Based on all these results, it has been conducted a phase Ib
dose-escalation and cohort-expansion clinical trial of galunisertib in combination with the anti-PD-L1
antibody durvalumab in refractory metastatic PC patients (H9H-MC-JBEG). In the 32 patients treated
with the recommended phase II dose, one partial response and 7 stable diseases were observed (disease
control rate 25%); PFS was 1.9 months (95% CI: 1.5, 2.2) and mOS was longer than 12 months (95% CI:
3.6, NR). This combination has demonstrated to be active and well-tolerated [246]. Although these
results represent the first signal of activity for an immune checkpoint-inhibitor combination strategy in
an “immune-excluded” tumor as PC, its efficacy would need to be confirmed in larger randomized
trials in advanced PC patients. Nonetheless, having demonstrated that TGF-β signaling inhibition is
an active strategy in combination with classic chemotherapy and immune checkpoint-inhibitors in
unselected advanced PC patient populations, the identification of biomarkers that could predict which
patients would benefit more from these combination strategies remains of unique importance for the
future development of more personalized treatments.
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5. Conclusions
PC remains arguably the deadliest of solid tumors. Advances in the understanding of the
genomic and transcriptomic complexity and heterogeneity of this disease, as well as elucidation of
basic biological mechanisms underlying PC transformation and progression to a highly malignant
phenotype, are of paramount importance to drive further clinical research and improve survival.
However, clinical experiments clearly show that, with few exceptions, targeting individual players
within the extremely complex and multifaceted crosstalk between the cancer cell genetic background,
soluble factors, and cellular and acellular components of a usually highly desmoplastic stroma
represents an oversimplification endowed with little potential for clinical efficacy.
Research efforts should thus concentrate on dissecting the currently elusive Ariadne’s string
that links early occurring genetic aberrations of transformed epithelial cells, with their ability to
secrete specific soluble factors (growth factors, cytokines, chemokines) which, in turn, will shape
the molecular and cellular composition of the TME; TME, on the other hand, will respond to tumor
growth (and presumably to the selective pressure applied by treatments) by activating different sets
of soluble factors which, in turn, will influence tumor cell behavior and reshape the TME. In depth
understanding examples of how the tumor genetic background can influence TME composition
and response to treatments include, for example, evidence that loss of the PTEN tumor suppressor
results in immunotherapy resistance, by directly inducing the T-cell inhibitor PD-L1 in several
malignancies, including in mouse pancreatic cancer models [247–249]. Another mechanism by which
tumor genotype can directly affect TME composition is the expression of specific cytokines, often
involved in characterizing an immunosuppressive environment [250]. In that respect, it has been
demonstrated that the oncogenic KRAS mutations are associated to an increased production of the
GM-CSF, which causes the expansion of immunosuppressive Gr1+CD11b+ myeloid cells in mouse PC
models; GM-CSF inhibition, in turn, could prevent MDSC recruitment and tumor development [251].
TME, on the other hand, may activate tumor cell signaling pathways which, in turn, cause
profound TME remodeling: for example, FAK by PC cell’s integrin binding to fibronectin and collagens
induces fibrosis and poor CD8+ cytotoxic T cell infiltration; inhibition of intracellular FAK signaling
reduces tumor fibrosis, decreases the numbers of tumor-infiltrating immunosuppressive cells, and
restores PC sensitivity T cell immunotherapy and PD-1 antagonists [183].
Cytokines secreted by either PC cells or stromal elements in the TME have pleiotropic, and
sometimes unpredictable, effects: for example, both CAF and aPSC act in an autocrine and paracrine
fashion in order to modulate the activity of the other cellular types in TME, such as endothelial and
immune cells [252]. Cancer cells release proangiogenic soluble factors to induce neovascular formation
in hypoxic condition of growth; on the other hand, hypoxia is one of the external stimuli of PSC
activation and induces aPSC to secrete proangiogenic elements, which not only promote endothelial
cells proliferation, but also sustain the maintenance of aPSC features [253].
Finally, TME components (both soluble factors and cellular and structural components, often
display a double-edged function: for example, Tregs usually create an immunosuppressive, therapy
resistant environment, but their depletion in PC may actually promotes pancreatic carcinogenesis,
as a result of CAF activation and immunosuppressive myeloid infiltration. As another example,
IL-10 function as an anti-inflammatory mediator, counteracting the production and activity of
pro-inflammatory cytokines such as IL-1β and IL-6, which have been shown to favor PC progression
and aggressiveness, has led to its development as a therapeutic agent; however, its double-edged
activity as a suppressor of CD4 responses and DC maturation may possibly explain its therapeutic
failure in recent clinical trials in PC.
It affords from the above that finding such elusive Ariadne’s string will be of paramount importance
in moving PC therapeutic scenario forward, avoiding a dreadful waste of time and patients’ lives
within dead-end paths. In addition to better understanding biology, we will have to improve our
clinical methodology, by designing smart and effective clinical trials to: (1) provide clinical proof of
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concept supporting the proposed biological mechanism; (2) identify relevant biomarkers; (3) lay solid
foundations for success in phase III clinical trials.
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